Sangcopan, Saidah .
HRN: 28-08-18 Sex: FemalePatient Encounter
AMS Audit List
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/17/2025
CEFUROXIME 500MG (TAB)
12/17/2025
12/24/2025
ORAL
500mg
BID
UTI
Checking Final Appropriateness
12/17/2025
CEFUROXIME 1.5GM (VIAL)
12/17/2025
12/18/2025
IV
1.5gms
Q8hrs X 3 Doses
S/P Primary LSTCS + IUD
Checking Final Appropriateness
12/17/2025
CEFUROXIME 500MG (TAB)
12/18/2025
12/25/2025
PO
500mg
BID X 7 Days
S/P Primary LSTCS + IUD
Checking Final Appropriateness
12/18/2025
CEFUROXIME 750MG (VIAL)
12/18/2025
12/19/2025
IV
500mg
Q8hrx 2 Days
Sp CS
Checking Final Appropriateness
12/18/2025
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
12/18/2025
12/19/2025
IV
500mg
BID X 2 Days
Sp CS
Checking Final Appropriateness
12/18/2025
METRONIDAZOLE 500MG (TAB)
12/19/2025
12/23/2025
ORAL
500mg
Bid X 5 Days
Sp CS
Checking Final Appropriateness